Forecast

The analysts' average price target is +32,61€ (+81,17%). The median is +32,61€ (+81,17%).

Buy	5
Hold	4
Sell	1

News Go to news feed

Innoviva: three therapies named finalists for Prix Galien USA 2026

Innoviva Specialty Therapeutics has confirmed three products — XACDURO, ZEVTERA and NUZOLVENCE — as finalists for the Prix Galien USA Award 2026 in the category “best pharmaceutical product.” XACDURO is approved for hospital- and ventilator-associated bacterial pneumonia caused by Acinetobacter, ZEVTERA is a cephalosporin approved in 2024 for Staphylococcus aureus, and NUZOLVENCE is a 2025-approved oral single-dose therapy for resistant gonorrhea. This is the third consecutive recognition of an Innoviva product by the Galien Foundation; the winners will be announced on October 29, 2026. » More on de.investing.com
Innoviva launches Nortiva Bio to develop long-acting oral LYNX platform

Innoviva launched Nortiva Bio, a wholly owned subsidiary to advance the LYNX long-acting oral drug delivery platform that can convert daily medicines into extended-release therapies with potential dosing up to one month. The move follows Innoviva’s 2025 acquisition of the LYNX platform from Lyndra Therapeutics. Separately, Innoviva Specialty Therapeutics signed an exclusive distribution and licensing deal with Dr. Reddy's for XACDURO in parts of Latin America, the Caribbean, Russia and CIS, with upfront, milestone and royalty payments outlined. » More on finance.yahoo.com
Innoviva reaches 52-week high, analysts see further upside

Innoviva's stock rose to a 52-week high of $24.02; the company has a market capitalization of about $1.79 billion and a price-to-earnings ratio of 15.69. Analysts and InvestingPro fair-value estimates continue to view the stock as undervalued with upside potential; BTIG initiated coverage with a "Buy" and a $35 price target and expects roughly $1.2 billion in licensing revenue from two inhalation therapies by 2030. In addition, Innoviva Specialty Therapeutics received FDA approval for NUZOLVENCE, a single-dose oral treatment for uncomplicated urogenital gonorrhea, strengthening the strategic growth outlook. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2015, Innoviva has already paid 0,67€ in dividends. The last payout was in September 2015.

Financials

In the last quarter, Innoviva had revenue of 104.79m€ and net profit of −73.09m€

(EUR)	Jun 2026	YoY
Revenue	+104.79m	23,16%
Gross profit	+79.40m	4,34%
Net profit	−73.09m	235,27%
EBITDA	+234.14m	229,29%

Fundamentals

Metric	Value
Market capitalization	+1.33b€
Number of shares	73.81m
52-week high/low	+21,58€ - +14,18€
Dividends	No
Beta	0,34
P/E ratio	+4,32
PEG ratio	+0,01
P/B ratio	+1,25
P/S ratio	+3,50

Company profile

Innoviva, Inc. beschäftigt sich mit der Entwicklung und Vermarktung von Arzneimitteln in den Vereinigten Staaten und international. Zu seinen Produkten gehören RELVAR/BREO ELLIPTA, ein einmal täglich zu verabreichendes Kombinationspräparat aus einem LABA, Vilanterol (VI), einem inhalativen Kortikosteroid (ICS) und Fluticasonfuroat; ANORO ELLIPTA, ein einmal täglich zu verabreichendes Medikament, das einen lang wirkenden Muskarin-Antagonisten (LAMA), Umeclidiniumbromid (UMEC), mit einem LABA und VI kombiniert; und TRELEGY ELLIPTA, ein einmal täglich zu verabreichendes Kombinationsmedikament, das aus einem ICS, LAMA und LABA besteht. Innoviva, Inc. hat eine strategische Partnerschaft mit Sarissa Capital Management LP. Das Unternehmen hat eine Kooperationsvereinbarung mit der Glaxo Group Limited über langwirksame Beta2-Agonisten (LABA) zur Entwicklung und Vermarktung von einmal täglich einzunehmenden Produkten für die Behandlung von chronisch-obstruktiven Lungenerkrankungen und Asthma. Das Unternehmen war früher als Theravance, Inc. bekannt und änderte im Januar 2016 seinen Namen in Innoviva, Inc. Innoviva, Inc. wurde 1996 gegründet und hat seinen Hauptsitz in Burlingame, Kalifornien.